Pharma Medical News about Dexlansoprazole

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Dexlansoprazole MR
Expert Opinion in Pharmacotherapy, 10/19/09

Aslam N et al. – Dexlansoprazole DDR has the potential to outperform traditional PPIs based on the metabolism and novel pharmacokinetics. It is currently FDA approved for the treatment of erosive esophagitis and symptomatic gastroesophageal reflux disease.

<< Previous
FDA Approves GARDASIL for Use in Boys and Young Men

Next >>
Anti-Malignancy Agent/Anti-VEGF Humanized Monoclonal Antibody,...

Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis
Clinical and Experimental Gastroenterology, 11/17/09 Relevance Score: 87%

Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience
Alimentary Pharmacology and Therapeutics, 10/23/09 Relevance Score: 87%

Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief
Alimentary Pharmacology and Therapeutics, 10/09/09 Relevance Score: 83%

New Study Results Analyzed the Use of KAPIDEX (dexlansoprazole) for Nighttime Heartburn in Adults with Non-Erosive GERD
Internet Source, 10/28/09 Relevance Score: 80%